Search clinical trials for: carboplatin and liposomal doxorubicin

Total 5616 results

ARCAGY/ GINECO GROUP

Completed

Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum (MYCA)

Ovarian Cancer

France
National Cancer Institute, Naples

Completed

END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin

Endometrial Cancer

Italy
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)

Completed

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Roswell Park Cancer Institute

Terminated

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Endometrial Cancer

United States
AGO Study Group

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

Germany
Telik

Completed

TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

Ovarian Neoplasms

United States
Fox Chase Cancer Center

Completed

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
THERAPIM PTY LTD
Novotech (Australia) Pty Limited

Terminated

A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Australia
Hunan Cancer Hospital

Recruiting

Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer

Ovarian Cancer

China
Aprea Therapeutics

Completed

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

United States, France, Spain, Netherlands, United Kingdom, Belgium, Germany, Sweden
AGO Study Group
Essex Pharma GmbH; MedServ. GmbH, Wiesbaden

Completed

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Cervical Cancers | Cancer of the Ovary Treated as 2nd Line Therapy | Muellerian Mixed Tumours | Tumours of the Uterus | Non-Epithelial Ovarian Tumours

Germany
King Faisal Specialist Hospital & Research Center

Completed

Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)

Epithelial Ovarian Cancer
Medical University Innsbruck

Unknown

Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer

Endometrial Cancer

Austria
University of Texas Southwestern Medical Center
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

Ovarian Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage III Uterine Corpus... and other conditions

United States
Konkuk University Medical Center
National Cancer Center, Korea; Samsung Medical Center; Asan Medical Center; Seoul... and other collaborators

Completed

Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian Carcinoma

Korea, Republic of
National Cancer Institute, Naples

Active, not recruiting

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

Ovarian Cancer

Italy, Portugal, Turkey
SOLTI Breast Cancer Research Group

Completed

Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer (Opti-HER)

Breast Cancer

Spain
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Norway
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
Merck Sharp & Dohme LLC
Princess Margaret Hospital, Canada

Completed

A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Ovarian Neoplasms
Tianjin Medical University Second Hospital
CSPC Pharmaceutical Group Limited

Unknown

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Muscle Invasive Bladder Cancer

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma

United States
French Innovative Leukemia Organisation

Completed

Liposomal Anthracyclin in the Treatment of Elderly ALL

Acute Lymphoblastic Leukemia

France
Ayana Pharma Ltd.,
Lambda Therapeutic Research Ltd.

Completed

A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

Ovarian Cancer Recurrent

India
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
University of Regensburg
Essex Pharma Germany

Completed

Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma

Glioblastoma

Germany
National Cheng-Kung University Hospital

Completed

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer (Trientine)

Fallopian Tube Cancer | Peritoneal Carcinoma | Ovarian Neoplasms Malignant (Excl Germ Cell)
Societe Internationale d'Oncologie Pediatrique

Completed

Chemotherapy in Treating Children With Liver Cancer

Liver Cancer

Italy
National Cancer Institute (NCI)

Recruiting

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)

Malignant Solid Neoplasm

United States
US Oncology Research
Ortho Biotech, Inc.; Tibotec Pharmaceutical Limited

Completed

Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

Metastatic Breast Cancer

United States
University of Leicester

Unknown

Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma

Liver Cancer

France, United Kingdom, Netherlands, Ireland
Astellas Pharma Inc
Agensys, Inc.

Terminated

A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer

Carcinoma | Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer

United States
Universitaire Ziekenhuizen KU Leuven
AstraZeneca

Active, not recruiting

Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer (CLIO)

Ovarian Epithelial Cancer

Belgium
Tesaro, Inc.

Terminated

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Cancer: Solid Tumors
Northwestern University
National Cancer Institute (NCI)

Withdrawn

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Breast Inflammatory Carcinoma

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms | Primary Peritoneal Neoplasm

United States
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Completed

Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer

Ovarian Cancer

China
Fudan University

Recruiting

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Advanced Malignant Tumors

China
Luye Pharma Group Ltd.

Completed

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Ovarian Epithelial Cancer Recurrent

India
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Bioequivalence

China
ARCAGY/ GINECO GROUP
European Organisation for Research and Treatment of Cancer - EORTC; Scherin... and other collaborators

Completed

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (CALYPSO)

Ovarian Cancer | Fallopian Tube Cancer

France
InxMed (Shanghai) Co., Ltd.

Active, not recruiting

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Locally Advanced or Metastatic Solid Tumors

China
Oncotherapeutics
Takeda

Completed

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Multiple Myeloma

United States

Search clinical trials for: carboplatin and liposomal doxorubicin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations